Bronchial Diseases
Conditions
Interventions
Group R-A:Rimazolam benzoate compounded with alfentanil
Group P-A:Propofol with alfentanil
Sponsors
Lishui People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients undergoing painless bronchoscopy in our hospital in 2023, aged 18 to 75 years, BMI 18.5 to 23.9 kg/m2 , ASA class I to II, complete electrocardiogram and various biochemical tests, no coagulation dysfunction, and patients or family members who were informed of the anesthetic use of this study and voluntarily signed the informed consent form to participate in this study were selected.
Exclusion criteria
Exclusion criteria: 1.Those with contraindications to conventional (bronchial) bronchoscopy, severe hepatic and renal dysfunction and hemostasis, as well as full stomach or gastrointestinal obstruction with gastric content retention. 2. Potentially life-threatening circulatory and respiratory diseases that are not properly controlled, such as acute coronary syndrome, uncontrolled severe hypertension, severe arrhythmias, severe heart failure, recent acute myocardial infarction, and acute attacks of asthma. 3.Patients with ASA class V. 4.Patients without accompanying or guardian. 5. Those with sedation/anesthesia drug allergy and other extremely high risk of anesthesia. 6.Allergy or contraindication to the subject drug. 7.Those who do not wish to participate in this study. Translated with www.DeepL.com/Translator (free version)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of hypoxemia;Excellent rate of anesthesia effect; | — |
Secondary
| Measure | Time frame |
|---|---|
| Wake-up time;Incidence of cough;Intraoperative stress reaction (blood pressure, heart rate fluctuation);Operating satisfaction of surgeons;Patient comfort score; dosage of remazolam or propofol ; | — |
Countries
China
Contacts
Public ContactDai Hong
Lishui People's Hospital
Outcome results
None listed